MemoryDETECTNCT00454454
Virtual Reality Helmet to Test for Problems With Memory
An observational study of Memory, run by Emory University at 2 sites in United States.
Trial summary
The purpose of this research study is to compare a virtual reality display device with the standard neuropsychological evaluation for detecting mild cognitive impairment (problems with memory, concentration, reaction time, etc.). Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Memory
- How many people
- 425 participants
- Where
- 2 sitesUnited States
- Study dates
- Mar 2007to Jul 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: geriatric clinic, retirement facilities
Who may be able to join
- 65 yrs of age and older
- MMSE of 18 or greater or mini-cog of 4 or greater
- Ability to read
- Informed consent given
Who cannot join
- Visual, hearing or physical impairment that would limit ability to use the virtual reality helmet or control device
- Non-English speaking
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Wesley Woods Health Center
Atlanta, Georgia, 30322
Wesley Woods Outpatient Clinic
Atlanta, Georgia, 30322
About this study
Official title: Display Enhanced TEsting for Cognitive Impairment and Traumatic Brain Injury
The purpose of this research study is to compare a virtual reality display device with the standard neuropsychological evaluation for detecting mild cognitive impairment (problems with memory, concentration, reaction time, etc.).
Read the detailed description
Since many individuals with mild cognitive impairment (MCI) appear to function normally, MCI may often be recognizable through testing in advance of any changes noticed by family members or caregivers. Early and frequent testing can therefore trigger an earlier diagnosis, which may increase the effectiveness of currently available medications used to delay onset of Alzheimer's symptoms. Primary care and geriatric physicians currently lack the necessary tools required for quick and accurate MCI screening in the doctor's office environment. The current industry-standard is a battery of pen \& paper neuropsychological tests that require 1.5 hours in a quiet room with a neuropsychologist.
Comparison: virtual reality display device compared to the standard neuropsychological evaluation for detecting mild cognitive impairment (problems with memory, concentration, reaction time, etc.).
- Conditions
- Memory
- Keywords
- memory, display enhanced testing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| No treatment | Not described |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2007 (estimated)
- Study startMar 2007
- Primary completionJul 2010
- Study completionJul 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for MemoryStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 425 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- Wallace H. Coulter Foundation
- Responsible party
- Principal investigator, David Wright, Emory University
- Investigators
- David W Wright, MD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00454454
- Sponsor's protocol ID
- 797-2002
- Acronym
- DETECT
- Status last verified
- Jul 2013
- First submitted
- 28 Mar 2007
- Last updated
- 30 Jul 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Wright DW, Nevarez H, Kilgo P, LaPlaca M, Robinson A, Fowler S, Brumfield J, Goldstein FC. A novel technology to screen for cognitive impairment in the elderly. Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):484-91. doi: 10.1177/1533317511426133. Epub 2011 Nov 22.
PubMed 22110158
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Display Enhanced TEsting for Cognitive Impairment and Traumatic Brain Injury
- ClinicalTrials.gov ID
- NCT00454454
- Acronym / sponsor ID
- DETECT / 797-2002
- Conditions
- Memory
- Keywords
- memory, display enhanced testing
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 425 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- Wallace H. Coulter Foundation
- Study start
- Mar 2007
- Primary completion
- Jul 2010 (actual)
- Study completion
- Jul 2010 (actual)
- First posted
- 30 Mar 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to compare a virtual reality display device with the standard neuropsychological evaluation for detecting mild cognitive impairment (problems with memory, concentration, reaction time, etc.).
Detailed description
Since many individuals with mild cognitive impairment (MCI) appear to function normally, MCI may often be recognizable through testing in advance of any changes noticed by family members or caregivers. Early and frequent testing can therefore trigger an earlier diagnosis, which may increase the effectiveness of currently available medications used to delay onset of Alzheimer's symptoms. Primary care and geriatric physicians currently lack the necessary tools required for quick and accurate MCI screening in the doctor's office environment. The current industry-standard is a battery of pen \& paper neuropsychological tests that require 1.5 hours in a quiet room with a neuropsychologist.
Comparison: virtual reality display device compared to the standard neuropsychological evaluation for detecting mild cognitive impairment (problems with memory, concentration, reaction time, etc.).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| No treatment | – | – |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- geriatric clinic, retirement facilities
Key inclusion criteria (4 listed)
- 65 yrs of age and older
- MMSE of 18 or greater or mini-cog of 4 or greater
- Ability to read
- Informed consent given
Key exclusion criteria (2 listed)
- Visual, hearing or physical impairment that would limit ability to use the virtual reality helmet or control device
- Non-English speaking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2013.
- Results publication: PubMed 22110158Wright DW, Nevarez H, Kilgo P, LaPlaca M, Robinson A, Fowler S, Brumfield J, Goldstein FC. A novel technology to screen for cognitive impairment in the elderly. Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):484-91. doi: 10.1177/1533317511426133. Epub 2011 Nov 22.
Related trials for Memory
Recruiting
SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression
Depressive Disorder, Treatment-Resistant, Memory Deficits
Active, not recruitingPhase 4
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Psoriasis Vulgaris, Psoriasis
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Recruiting
tACS for Working Memory in Schizophrenia
Schizophrenia, Working Memory
Active, not recruitingObservational study
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy
Breast Cancer, Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David W Wright, MD principal investigator
Emory University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Memory, run by Emory University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00454454, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2013.